Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in AML and BPDCN
NCT02113982Phase 2Completed
- Sponsor
- Stemline Therapeutics
- Start
- Sep 2014
- Primary completion
- Feb 2020
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of tagraxofusp in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML) (3 arms), sponsored by Stemline Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days and Complete Response Rate up to 3.5 years. Started Sep 2014; status: completed.
02
Drugs
tagraxofusp
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02113982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113982.